Shannon D Sullivan1, Amy Lehman, Fridtjof Thomas, Karen C Johnson, Rebecca Jackson, Jean Wactawski-Wende, Marcia Ko, Zhao Chen, J David Curb, Barbara V Howard. 1. 1Division of Endocrinology and Metabolism, Department of Medicine, Medstar Washington Hospital Center, Washington, DC 2Center for Biostatistics, The Ohio State University, Columbus, OH 3Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN 4Department of Medicine, The Ohio State University, Columbus, OH 5Department of Social and Preventive Medicine, State University of New York, University at Buffalo, Buffalo, NY 6Department of Women's Health Internal Medicine, Mayo Clinic, Phoenix, AZ 7Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ 8Department of Geriatric Medicine, University of Hawaii, Honolulu, HI 9Department of Medicine, Biostatistics, and Epidemiology, Medstar Health Research Institute, Hyattesville, MD.
Abstract
OBJECTIVE: Menopause is a risk factor for fracture; thus, menopause age may affect bone mass and fracture rates. We compared bone mineral density (BMD) and fracture rates among healthy postmenopausal women with varying ages at self-reported nonsurgical menopause. METHODS: We compared hazard ratios for fractures and differences in BMD among 21,711 postmenopausal women from the Women's Health Initiative Observational Study cohort who had no prior hysterectomy, oophorectomy, or hormone therapy and had varying self-reported ages at menopause (<40, 40-49, or ≥50 y). RESULTS: Before multivariable adjustments, we found no differences in absolute fracture risk among menopause age groups. After multivariable adjustments for known risk factors for fracture, women who underwent menopause before age 40 years had a higher fracture risk at any site compared with women who underwent menopause at age 50 years or older (hazard ratio, 1.21; 95% CI, 1.02 to 1.44; P = 0.03). In a subset with BMD measurements (n = 1,351), whole-body BMD was lower in women who reported menopause before age 40 years than in women who reported menopause at ages 40 to 49 years (estimated difference, -0.034 g/cm; 95% CI, -0.07 to -0.004; P = 0.03) and women who reported menopause at age 50 years or older (estimated difference, -0.05 g/cm; 95% CI, -0.08 to -0.02; P < 0.01). Left hip BMD was lower in women who underwent menopause before age 40 years than in women who underwent menopause at age 50 years or older (estimated difference, -0.05 g/cm; 95% CI, -0.08 to -0.01; P = 0.01), and total spine BMD was lower in women who underwent menopause before age 40 years than in women who underwent menopause at age 50 years or older (estimated difference, -0.11 g/cm; 95% CI, -0.16 to -0.06; P < 0.01) and women who underwent menopause at ages 40 to 49 years (estimated difference, -0.09 g/cm; 95% CI, -0.15 to -0.04; P < 0.01). CONCLUSIONS: In the absence of hormone therapy, younger age at menopause may be a risk factor contributing to decreased BMD and increased fracture risk in healthy postmenopausal women. Our data suggest that menopause age should be taken into consideration, along with other osteoporotic risk factors, when estimating fracture risk in postmenopausal women.
OBJECTIVE: Menopause is a risk factor for fracture; thus, menopause age may affect bone mass and fracture rates. We compared bone mineral density (BMD) and fracture rates among healthy postmenopausal women with varying ages at self-reported nonsurgical menopause. METHODS: We compared hazard ratios for fractures and differences in BMD among 21,711 postmenopausal women from the Women's Health Initiative Observational Study cohort who had no prior hysterectomy, oophorectomy, or hormone therapy and had varying self-reported ages at menopause (<40, 40-49, or ≥50 y). RESULTS: Before multivariable adjustments, we found no differences in absolute fracture risk among menopause age groups. After multivariable adjustments for known risk factors for fracture, women who underwent menopause before age 40 years had a higher fracture risk at any site compared with women who underwent menopause at age 50 years or older (hazard ratio, 1.21; 95% CI, 1.02 to 1.44; P = 0.03). In a subset with BMD measurements (n = 1,351), whole-body BMD was lower in women who reported menopause before age 40 years than in women who reported menopause at ages 40 to 49 years (estimated difference, -0.034 g/cm; 95% CI, -0.07 to -0.004; P = 0.03) and women who reported menopause at age 50 years or older (estimated difference, -0.05 g/cm; 95% CI, -0.08 to -0.02; P < 0.01). Left hip BMD was lower in women who underwent menopause before age 40 years than in women who underwent menopause at age 50 years or older (estimated difference, -0.05 g/cm; 95% CI, -0.08 to -0.01; P = 0.01), and total spine BMD was lower in women who underwent menopause before age 40 years than in women who underwent menopause at age 50 years or older (estimated difference, -0.11 g/cm; 95% CI, -0.16 to -0.06; P < 0.01) and women who underwent menopause at ages 40 to 49 years (estimated difference, -0.09 g/cm; 95% CI, -0.15 to -0.04; P < 0.01). CONCLUSIONS: In the absence of hormone therapy, younger age at menopause may be a risk factor contributing to decreased BMD and increased fracture risk in healthy postmenopausal women. Our data suggest that menopause age should be taken into consideration, along with other osteoporotic risk factors, when estimating fracture risk in postmenopausal women.
Authors: MaryFran R Sowers; Huiyong Zheng; Gail A Greendale; Robert M Neer; Jane A Cauley; Jayne Ellis; Sarah Johnson; Joel S Finkelstein Journal: J Clin Endocrinol Metab Date: 2013-05-10 Impact factor: 5.958
Authors: Vaishali B Popat; Karim A Calis; Sophia N Kalantaridou; Vien H Vanderhoof; Deloris Koziol; James F Troendle; James C Reynolds; Lawrence M Nelson Journal: J Clin Endocrinol Metab Date: 2014-06-06 Impact factor: 5.958
Authors: D M Black; M Steinbuch; L Palermo; P Dargent-Molina; R Lindsay; M S Hoseyni; O Johnell Journal: Osteoporos Int Date: 2001 Impact factor: 4.507
Authors: Daniel Prieto-Alhambra; Melissa O Premaor; Francesc Fina Avilés; Eduard Hermosilla; Daniel Martinez-Laguna; Cristina Carbonell-Abella; Xavier Nogués; Juliet E Compston; Adolfo Díez-Pérez Journal: J Bone Miner Res Date: 2012-02 Impact factor: 6.741
Authors: Chris De Laet; Anders Odén; Helena Johansson; Olof Johnell; Bengt Jönsson; John A Kanis Journal: Osteoporos Int Date: 2004-07-06 Impact factor: 4.507
Authors: Vaishali B Popat; Karim A Calis; Vien H Vanderhoof; Giovanni Cizza; James C Reynolds; Nancy Sebring; James F Troendle; Lawrence M Nelson Journal: J Clin Endocrinol Metab Date: 2009-04-28 Impact factor: 5.958
Authors: Vladimir K Bakalov; Michael L Chen; Jeffrey Baron; Lori B Hanton; James C Reynolds; Constantine A Stratakis; Lauren E Axelrod; Carolyn A Bondy Journal: Am J Med Date: 2003-09 Impact factor: 4.965
Authors: Michael T Collins; Gemma Marcucci; Hans-Joachim Anders; Giovanni Beltrami; Jane A Cauley; Peter R Ebeling; Rajiv Kumar; Agnès Linglart; Luca Sangiorgi; Dwight A Towler; Ria Weston; Michael P Whyte; Maria Luisa Brandi; Bart Clarke; Rajesh V Thakker Journal: Nat Rev Endocrinol Date: 2022-05-16 Impact factor: 47.564
Authors: Eliza C Miller; Ashley Wilczek; Natalie A Bello; Sarah Tom; Ronald Wapner; Yousin Suh Journal: Ageing Res Rev Date: 2021-12-03 Impact factor: 10.895
Authors: D Kuh; S Muthuri; R Cooper; A Moore; K Mackinnon; C Cooper; J E Adams; R Hardy; K A Ward Journal: J Clin Endocrinol Metab Date: 2016-07-29 Impact factor: 5.958